Edition:
United Kingdom

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

71.93CNY
14 Feb 2018
Change (% chg)

¥0.70 (+0.98%)
Prev Close
¥71.23
Open
¥71.70
Day's High
¥72.42
Day's Low
¥71.30
Volume
5,579,497
Avg. Vol
13,252,367
52-wk High
¥78.75
52-wk Low
¥39.77

Latest Key Developments (Source: Significant Developments)

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

Jiangsu Hengrui Medicine says license agreement on JAK1 inhibitor SHR0302 with U.S.-based firm Arcutis
Friday, 5 Jan 2018 

Jan 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says co signs license agreement with U.S.-based firm Arcutis regarding JAK1 inhibitor SHR0302 .Says co grants Arcutis an exclusive right to develop and sell JAK1 inhibitor SHR0302 in United States of America, European Union and Japan.Says co will receive upfront and milestones payment of up to $223 million and sales commissions from Arcutis.  Full Article

Jiangsu Hengrui Medicine passes U.S. FDA approval
Wednesday, 29 Nov 2017 

Nov 29(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration.Company will be able to sell its Dexmedetomidine Hydrochloride Injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine gets approval for clinical trials of drugs
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration.  Full Article

Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million).  Full Article

Jiangsu Hengrui Medicine to pay A shares annual div for FY 2016 on May 31
Monday, 22 May 2017 

May 22 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS> ::* Says it will pay cash dividend of 0.135 yuan(before tax)/share and use additional paid-in capital to distribute 0.2 new shares/share for 2016 to shareholders of record on May 26 .* The company's shares will be traded ex-right and ex-dividend on May 31 and the dividend will be paid on May 31.  Full Article

Jiangsu Hengrui Medicine's H1 net profit up 24 pct y/y
Monday, 29 Aug 2016 

Jiangsu Hengrui Medicine Co Ltd <600276.SS> :Says H1 net profit up 23.85 percent y/y at 1.3 billion yuan ($194.66 million).  Full Article

Jiangsu Hengrui Medicine and unit receive approval for drug clinic trial
Tuesday, 5 Jul 2016 

Jiangsu Hengrui Medicine <600276.SS> Co., Ltd.:Says the co and unit get China Food and Drug Administration's approval for its SHR-1314 injection which will be mainly used for the treatment of psoriasis.  Full Article

Jiangsu Hengrui Medicine says 2015 dividend payment date
Wednesday, 8 Jun 2016 

Jiangsu Hengrui Medicine Co Ltd <600276.SS>: Says it will pay a cash dividend of 1 yuan (pre-tax) for every 10 shares and to distribute 2 shares for every 10 shares as stock dividend, to shareholders of record on June 15 for 2015 .Says the company's shares will be traded ex-right and ex-dividend on June 16 and the dividend will be paid on June 16.  Full Article

Jiangsu Hengrui Medicine unit gets nod for clinic trial
Saturday, 30 Apr 2016 

Jiangsu Hengrui Medicine Co Ltd:Says its unit gets China Food and Drug Administration's approval for its tafluprost' clinic trial.  Full Article

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES